

Urgent need for new antibiotics

But we cannot keep (mis)using
them the way we have for the last 70 years!

Marketing and use needs to be restricted
Return of investment decoupled from sales



We need a new business logic!

Urgent need for new antibiotics

The overall innovative capacity is low

There are major scientific challenges

Who is going to do the work?

Big Pharma? Small pharma? Academia?



New collaborative models needed

Urgent need for new antibiotics

Market failure

Impending health crisis

High health and economic burden from resistance



Justifies intervention from the public sector

Towards a new business logic for R&D of novel antibiotics

- Needs driven :based on analysis of pipeline vs resistance and its burden
- Prioritization, target product profiles
- Solving the scientific challenges
- New Collaborative models and institutions (e.g. open source)
- Incentives that reward priority antibiotics
 - Special regulatory designation
 - Pricing and reimbursement
 - Push and pull incentives
- De-linking return of investment from sales
- Controlled use and distribution
- Equitable global access and affordability